Harmony Biosciences Holdings Inc (HRMY)
33.45
+0.41
(+1.24%)
USD |
NASDAQ |
Nov 05, 14:31
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 1.908B |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | 27.47% |
Valuation | |
PE Ratio | 15.85 |
PE Ratio (Forward) | Upgrade |
PS Ratio | 2.846 |
Price to Book Value | 3.196 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | 0.3064 |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | -- |
Profile
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant), is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and used for the treatment of cataplexy in adult patients with narcolepsy. |
URL | https://www.harmonybiosciences.com |
Investor Relations URL | https://ir.harmonybiosciences.com/ |
HQ State/Province | Pennsylvania |
Sector | Health Care |
Industry | Pharmaceuticals |
Equity Style | Small Cap/Blend |
Next Earnings Release | Feb. 21, 2025 (est.) |
Last Earnings Release | Oct. 29, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Ratings
Profile
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant), is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and used for the treatment of cataplexy in adult patients with narcolepsy. |
URL | https://www.harmonybiosciences.com |
Investor Relations URL | https://ir.harmonybiosciences.com/ |
HQ State/Province | Pennsylvania |
Sector | Health Care |
Industry | Pharmaceuticals |
Equity Style | Small Cap/Blend |
Next Earnings Release | Feb. 21, 2025 (est.) |
Last Earnings Release | Oct. 29, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |